Citations 1
Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.
Adjei, Alex A. , Philip, Philip Agop, Mercadé, T. Macarulla, Walter, Annette O., Cupit, Lisa, Fields, Scott Z., Holynskyj, Ariadna, Bekaii‐Saab, Tanios , Berlin, Jordan D. , Liu, Rong
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS2607-TPS2607
